UK approves Prima BioMed to initiate Phase II b trial of IMP321 to treat metastatic breast cancer
Australian biotechnology firm Prima BioMed has secured approval from the UK ’s Competent Authority and Ethics Committee to begin a Phase II b, active immunotherapy paclitaxel (AIPAC) trial of its IMP321 drug to treat metastatic breast cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | Immunotherapy | Medical Ethics | Pharmaceuticals